About 8 results found for searched term "PHGDH" (0.1 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M29015 | PHGDH-inactive | PHGDH |
| PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503. | ||
| M6566 | CBR 5884 | PHGDH |
| CBR 5884 is a 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor. | ||
| M8604 | NCT-503 | PHGDH |
| NCT503 | ||
| NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis. | ||
| M8753 | PKUMDL-WQ-2201 | Others |
| PKUMDL-WQ-2201 is a potent and selective non-NAD+-competing allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) that selectively inhibits serine synthesis in cancer cells. | ||
| M14660 | BI-4916 | PHGDH |
| BI-4916 is a prodrug of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor. | ||
| M14661 | BI-4924 | PHGDH |
| BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. | ||
| M14738 | NCT-502 | PHGDH |
| NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH. | ||
| M29874 | PKUMDL-WQ-2101 | PHGDH |
| PKUMDL-WQ-2101 is a non-NAD+-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
